Plant Name: Solanum lycopersicum
Taxonomic Information:
Plant ID: NPO21080
Plant Latin Name: Solanum lycopersicum
Taxonomy Genus: Solanum
Taxonomy Family: Solanaceae
Plant External Links:
NCBI TaxonomyDB:
4081
Plant-of-the-World-Online:
316947-2
Used in Medicines:
Country/Region:
Turkey; Ghana; Italy; Indonesia; India; United StatesTraditional Medicine System:
Unani; Indian Folk; Homeopathy; Ayurveda; SiddhaGeographical Distribution:
Ghana; Turkey; Italy; South Africa; Indonesia; India; United States; Austria; Peru
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR1B; HTR2C; HTR2A; HTR6; HTR1D; | |
| CA14; CA4; | |
| ALOX5; PTGS2; | |
| MPO; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 8.725E-13 | 4.750E-09 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 8.725E-13 | 4.750E-09 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.874E-11 | 5.830E-08 | HTR1B, HTR1D, HTR2A, HTR2C |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 2.948E-07 | 4.451E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 2.948E-07 | 4.451E-04 | HTR2A, HTR2C |
| BP | Unclassified; | GO:0042310; vasoconstriction | 4.980E-07 | 5.346E-04 | HTR1B, HTR1D, HTR2A |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 5.156E-07 | 5.346E-04 | HTR1B, HTR1D, HTR2A, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 2.946E-06 | 2.566E-03 | HTR2A, HTR2C |
| BP | GO:0009987; cellular process | GO:0045600; positive regulation of fat cell differentiation | 4.389E-06 | 3.296E-03 | HTR2A, HTR2C, PTGS2 |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 5.617E-06 | 3.822E-03 | HTR1B, HTR1D, HTR2A |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.626E-14 | 1.388E-12 | HTR6, ALOX5, HTR1D, HTR1B, HTR2C, HTR2A, PTGS2 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.122E-07 | 3.182E-06 | HTR6, HTR1D, HTR1B, HTR2C, HTR2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.122E-04 | 8.413E-04 | HTR6, HTR2C, HTR2A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.510E-04 | 9.057E-04 | HTR6, HTR1D, HTR1B |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.321E-04 | 1.660E-03 | ALOX5, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.108E-04 | 2.189E-03 | ALOX5, PTGS2 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.723E-05 | 3.723E-04 | CA4, CA14 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 9.134E-04 | 3.420E-03 | HTR1D, HTR1B |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.270E-03 | 3.810E-03 | HTR2C, HTR2A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.026E-03 | 3.420E-03 | HTR2C, HTR2A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| NA: NA | Addiction | NA | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; ALOX5; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; ALOX5; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; ALOX5; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; HTR1B; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PTGS2; ALOX5; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR6; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ALOX5; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; HTR6; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; ALOX5; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR1D; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; HTR1B; HTR1D; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2A; HTR2C; HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; HTR1B; HTR1D; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; HTR6; HTR1B; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; HTR1B; HTR1D; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
